Discovery of Isoindoline Amide Derivatives as Potent and Orally Bioavailable ADAMTS-4/5 Inhibitors for the Treatment of Osteoarthritis
Lists
Only you see this
Abstract
Osteoarthritis (OA) treatment is a highly unmet medical need. Development of a disease-modifying OA drug (DMOAD) is challenging with no approved drugs on the market. Inhibition of ADATMS-4/5 is a promising OA therapeutics to target cartilage degradation and potentially can reduce joint pain and restore its normal function. Starting from the reported ADAMTS-5 inhibitor GLPG1972, we applied a scaffold hopping strategy to generate a novel isoindoline amide scaffold. Representative compound <b>18</b> showed high potency in ADATMS-4/5 inhibition, as well as good selectivity over a panel of other metalloproteases. In addition, compound <b>18</b> exhibited excellent druglike properties and showed better pharmacokinetic (PK) profiles than GLPG1972 cross-species. Compound <b>18</b> demonstrated dose-dependent efficacy in two <i>in vivo</i> rat osteoarthritis models.
BibTeX
@inproceedings{zhao2022discovery,
author = {Peng Zhao and Dong Liu and Chunying Song and Di Li and Xinzhu Zhang and Ivana Horecny and Fengqi Zhang and Yuna Yan and Linghang Zhuang and Jing Li and Suxing Liu and Yuchang Mao and Jun Feng and Jian Liu and Weikang Tao},
title = {{Discovery of Isoindoline Amide Derivatives as Potent and Orally Bioavailable ADAMTS-4/5 Inhibitors for the Treatment of Osteoarthritis}},
booktitle = {ACS},
year = {2022},
doi = {10.1021/acsptsci.2c00023},
}Loading related content...